secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEXX LABORATORIES INC /DE (IDXX)
CIK:        0000874716
Form:       8-K
Filed at:   2023-02-06T23:59:59+00:00
Accession:  0000950170-23-001820
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEXX Q4 revenue +7% organic; EPS $2.05; FY23 guidance rev $3.59B-$3.69B, EPS $9.27-$9.75
--------------------------------------------------------------------------------

- Q4 revenue $829M (+3% reported, +7% organic); EPS $2.05 (+8% reported, +14% comparable).
- FY2022 revenue $3,367M (+5% reported, +7% organic); EPS $8.03 (-7% reported, -1% comparable, including discrete R&D headwind).
- CAG Diagnostics recurring revenue grew 4% reported, 8% organic in Q4; global premium instrument installed base up 13% YoY.
- FY2023 guidance: revenue $3.59B-$3.69B (6.5%-9.5% reported growth); EPS $9.27-$9.75 (16%-21% reported growth).
- Q4 operating margin 27.3% (+240bps reported); 2023 operating margin target 29.0%-29.6%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874716/000095017023001820/0000950170-23-001820-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874716/000095017023001820/idxx-20230206.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-001820

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer